Details of the Drug | DrugMAP

General Information of Drug (ID: DM1V25N)

Drug Name

REC-994

Indication

Disease Entry	ICD 11	Status	REF
Cerebral cavernous malformation	8B22.41	Phase 2	[1]
------------------------------------------------------------------------------------

Affected Organisms

Humans and other mammals

Drug Type

Small molecule

Cross-matching ID

DrugBank ID: DB15616
TTD ID: D47RUF

References

1	ClinicalTrials.gov (NCT05085561) A Two-Part Study of REC-994 in the Treatment of Adults With Symptomatic Cerebral Cavernous Malformation (CCM); Part 1: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Two Doses of REC-994; Part 2: A Long-Term Blinded Extension Clinical Trial to Evaluate Long-Term Safety Tolerability and Efficacy of REC-994. U.S.National Institutes of Health.